Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Notes Payables (2016 - 2018)

Lisata Therapeutics' Notes Payables history spans 9 years, with the latest figure at $23289.0 for Q2 2018.

  • For Q2 2018, Notes Payables fell 96.12% year-over-year to $23289.0; the TTM value through Jun 2018 reached $23289.0, down 96.12%, while the annual FY2017 figure was $159000.0, 77.29% down from the prior year.
  • Notes Payables reached $23289.0 in Q2 2018 per LSTA's latest filing, down from $100000.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $2.1 million in Q2 2015 to a low of $23289.0 in Q2 2018.
  • Average Notes Payables over 5 years is $1.0 million, with a median of $1.0 million recorded in 2015.
  • Peak YoY movement for Notes Payables: surged 546.71% in 2014, then tumbled 96.12% in 2018.
  • A 5-year view of Notes Payables shows it stood at $1.6 million in 2014, then tumbled by 31.25% to $1.1 million in 2015, then tumbled by 36.36% to $700000.0 in 2016, then tumbled by 77.29% to $159000.0 in 2017, then tumbled by 85.35% to $23289.0 in 2018.
  • Per Business Quant, the three most recent readings for LSTA's Notes Payables are $23289.0 (Q2 2018), $100000.0 (Q1 2018), and $159000.0 (Q4 2017).